Seaport Research lowered the firm’s price target on Ascend Wellness to $5 from $6 and keeps a Buy rating on the shares. After four quarters of beating revenue and AEBITDA estimates, the company reported Q2 results that were below the firm’s expectations, the analyst tells investors. Despite this, Seaport continues to believe the company’s strong execution, retail prowess, and marketing & acquisition upside make it the “most underappreciated” story in the cannabis sector.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AAWH: